Clinical trial · Interventional
Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures
Safety and Efficacy of Dexmedetomidine vs Ketamine vs Midazolam Combined With Propofol in Gastrointestinal Procedures for Cancer Patients
NCT04597268CI-TRIAL-00063140completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the safety and efficacy of dexmedetomidine versus ketamine versus midazolam combined with propofol in cancer patients undergoing gastrointestinal endoscopic procedures.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sedation and Analgesia | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
| Ketamine | Drug | — | UNRESOLVED |
| Midazolam | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- dexmedetomidine
- description
- IV dexmedetomidine
- interventionNames
- Drug: Dexmedetomidine
- type
- EXPERIMENTAL
- label
- ketamine
- description
- IV ketamine
- interventionNames
- Drug: Ketamine
- type
- ACTIVE_COMPARATOR
- label
- Midazolam
- description
- IV midazolam
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients scheduled for gastrointestinal endoscopic procedures * ≥ Age 18 years * ASA I-II Exclusion Criteria: * Allergy to any of the used drugs * impaired renal or liver functions * hypertensive patients * patients with cardiovascular * cerebrovascular disease
References
Publications (0)
Data not yet available
No reference posted for this study.